{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:15:53Z","timestamp":1768904153885,"version":"3.49.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>To assess the prevalence and evolution of transmitted drug resistance (TDR) in Belgium, a total of 3708 baseline human immunodeficiency virus (HIV)-1 polymerase sequences from patients diagnosed between 2013 and 2019 were analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Protease and reverse-transcriptase HIV-1 sequences were collected from the 7 national Aids Reference Laboratories. Subtype determination and drug resistance scoring were performed using the Stanford HIV Drug Resistance Database. Trends over time were assessed using linear regression, and the maximum likelihood approach was used for phylogenetic analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 17.9% of the patients showed evidence of TDR resulting in at least low-level resistance to 1 drug (Stanford score \u2009\u226515). If only the high-level mutations (Stanford score \u226560) were considered, TDR prevalence dropped to 6.3%. The majority of observed resistance mutations impacted the sensitivity for nonnucleoside reverse-transcriptase inhibitors (NNRTIs) (11.4%), followed by nucleoside reverse-transcriptase inhibitors (6.2%) and protease inhibitors (2.4%). Multiclass resistance was observed in 2.4%. Clustered onward transmission was evidenced for 257 of 635 patients (40.5%), spread over 25 phylogenetic clusters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The TDR prevalence remained stable between 2013 and 2019 and is comparable to the prevalence in other Western European countries. The high frequency of NNRTI mutations requires special attention and follow-up. Phylogenetic analysis provided evidence for local clustered onward transmission of some frequently detected mutations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofac195","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T17:10:56Z","timestamp":1649783456000},"source":"Crossref","is-referenced-by-count":4,"title":["Prevalence and Evolution of Transmitted Human Immunodeficiency Virus Drug Resistance in Belgium Between 2013 and 2019"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9376-8910","authenticated-orcid":false,"given":"Virginie","family":"Mortier","sequence":"first","affiliation":[{"name":"Aids Reference Laboratory, Department of Diagnostic Sciences, Ghent University , Ghent , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Debaisieux","sequence":"additional","affiliation":[{"name":"Aids Reference Laboratory, Universit\u00e9 Libre de Bruxelles, Cliniques universitaires de Bruxelles H\u00f4pital Erasme , Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9raldine","family":"Dessilly","sequence":"additional","affiliation":[{"name":"Aids Reference Laboratory, Medical Microbiology Unit, Universit\u00e9 Catholique de Louvain , Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolien","family":"Stoffels","sequence":"additional","affiliation":[{"name":"Aids Reference Laboratory, Centre Hospitalier Universitaire St. Pierre , Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Vaira","sequence":"additional","affiliation":[{"name":"Aids Reference Laboratory, Centre Hospitalier Universitaire de Li\u00e8ge , Li\u00e8ge , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Vancutsem","sequence":"additional","affiliation":[{"name":"Aids Reference Laboratory, Vrije Universiteit Brussel VUB , Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristel","family":"Van Laethem","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven , Leuven , Belgium"},{"name":"Aids Reference Laboratory, University Hospitals Leuven , Leuven , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fien","family":"Vanroye","sequence":"additional","affiliation":[{"name":"Aids Reference Laboratory, Clinical Reference Laboratory, Department of Clinical Sciences, Institute of Tropical Medicine , Antwerp , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Verhofstede","sequence":"additional","affiliation":[{"name":"Aids Reference Laboratory, Department of Diagnostic Sciences, Ghent University , Ghent , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"2022073010085135200_ofac195-B1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7326\/0003-4819-135-1-200107030-00005","article-title":"Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease","volume":"135","author":"Murphy","year":"2001","journal-title":"Ann Intern Med"},{"key":"2022073010085135200_ofac195-B2","article-title":"EACS Guidelines version 10.1","author":"European AIDS Clinical Society"},{"key":"2022073010085135200_ofac195-B3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/ciy463","article-title":"Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society-USA Panel","volume":"68","author":"G\u00fcnthard","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022073010085135200_ofac195-B4","first-page":"662","article-title":"Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure","volume":"201","author":"Paredes","year":"2010","journal-title":"J Infect Dis"},{"key":"2022073010085135200_ofac195-B5","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1086\/596736","article-title":"Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes","volume":"199","author":"Simen","year":"2009","journal-title":"J Infect Dis"},{"key":"2022073010085135200_ofac195-B6","doi-asserted-by":"crossref","first-page":"e25611","DOI":"10.1002\/jia2.25611","article-title":"HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates","volume":"23","author":"Rhee","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"2022073010085135200_ofac195-B7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/cid\/civ963","article-title":"Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe","volume":"62","author":"Hofstra","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2022073010085135200_ofac195-B8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/hiv.12414","article-title":"Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom","volume":"18","author":"Tostevin","year":"2017","journal-title":"HIV Med"},{"key":"2022073010085135200_ofac195-B9","doi-asserted-by":"crossref","first-page":"e0209605","DOI":"10.1371\/journal.pone.0209605","article-title":"Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort","volume":"14","author":"Machnowska","year":"2019","journal-title":"PLoS One"},{"key":"2022073010085135200_ofac195-B10","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jmv.25896","article-title":"Prevalence of transmitted drug resistance mutations among newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy","volume":"92","author":"Calza","year":"2020","journal-title":"J Med Virol"},{"key":"2022073010085135200_ofac195-B11","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1089\/aid.2019.0063","article-title":"Trends in HIV-1 drug resistance mutations from a U.S. reference laboratory from 2006 to 2017","volume":"35","author":"Kagan","year":"2019","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022073010085135200_ofac195-B12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/cid\/ciy453","article-title":"Trends in the molecular epidemiology and genetic mechanisms of transmitted human immunodeficiency virus type 1 drug resistance in a large US clinic population","volume":"68","author":"Rhee","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022073010085135200_ofac195-B13","doi-asserted-by":"crossref","first-page":"e0158560","DOI":"10.1371\/journal.pone.0158560","article-title":"Surveillance of HIV transmitted drug resistance in Latin America and the Caribbean: a systematic review and meta-analysis","volume":"11","author":"Avila-Rios","year":"2016","journal-title":"PLoS One"},{"key":"2022073010085135200_ofac195-B14","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/hiv.13038","article-title":"Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study","volume":"22","author":"Baxter","year":"2021","journal-title":"HIV Med"},{"key":"2022073010085135200_ofac195-B15","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/QAD.0b013e32832d40ad","article-title":"The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection","volume":"23","author":"Yerly","year":"2009","journal-title":"AIDS"},{"key":"2022073010085135200_ofac195-B16","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1089\/aid.2013.0108","article-title":"Transmission network of an HIV type 1 strain with K103N in young Belgian patients from different risk groups","volume":"29","author":"Ruelle","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022073010085135200_ofac195-B17","doi-asserted-by":"crossref","first-page":"e0127950","DOI":"10.1371\/journal.pone.0127950","article-title":"Ongoing HIV transmission and the HIV care continuum in North Carolina","volume":"10","author":"Cope","year":"2015","journal-title":"PLoS One"},{"key":"2022073010085135200_ofac195-B18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jgar.2019.07.014","article-title":"Transmitted drug resistance in newly diagnosed and treatment-naive HIV type 1-infected patients in Hungary","volume":"20","author":"\u00c1y","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2022073010085135200_ofac195-B19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"2022073010085135200_ofac195-B20","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2022073010085135200_ofac195-B21","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update","volume":"4","author":"Bennett","year":"2009","journal-title":"PLoS One"},{"key":"2022073010085135200_ofac195-B22","first-page":"111","article-title":"2019 update of the drug resistance mutations in HIV-1","volume":"27","author":"Wensing","year":"2019","journal-title":"Top Antivir Med"},{"key":"2022073010085135200_ofac195-B23","first-page":"95","article-title":"Bioedit: a user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/INT","volume":"41","author":"Hall","year":"1999","journal-title":"Nucleic Acids SympSer"},{"key":"2022073010085135200_ofac195-B24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/QAI.0b013e3181c42ea4","article-title":"Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy","volume":"54","author":"Hatano","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022073010085135200_ofac195-B25","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1128\/JVI.00495-16","article-title":"HIV-1 protease, reverse transcriptase, and integrase variation","volume":"90","author":"Rhee","year":"2016","journal-title":"J Virol"},{"key":"2022073010085135200_ofac195-B26","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1093\/jac\/dkr386","article-title":"Molecular and epidemiological characterization of HIV-1 infection networks involving transmitted drug resistance mutations in Northern Greece","volume":"66","author":"Skoura","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2022073010085135200_ofac195-B27","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/infdis\/jix015","article-title":"Commonly transmitted HIV-1 drug resistance mutations in reverse-transcriptase and protease in antiretroviral treatment-naive patients and response to regimens containing tenofovir disoproxil fumarate or tenofovir alafenamide","volume":"215","author":"Margot","year":"2017","journal-title":"J Infect Dis"},{"key":"2022073010085135200_ofac195-B28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jgar.2019.08.024","article-title":"Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naive patients: a single-centre experience","volume":"20","author":"Mazzuti","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2022073010085135200_ofac195-B29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/infdis\/jiv012","article-title":"Assessing the paradox between transmitted and acquired HIV type 1 drug resistance mutations in the Swiss HIV Cohort Study from 1998 to 2012","volume":"212","author":"Yang","year":"2015","journal-title":"J Infect Dis"},{"key":"2022073010085135200_ofac195-B30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/infdis\/jiaa683","article-title":"Clinical impact of pretreatment human immunodeficiency virus drug resistance in people initiating nonnucleoside reverse transcriptase inhibitor-containing antiretroviral therapy: a systematic review and meta-analysis","volume":"224","author":"Bertagnolio","year":"2021","journal-title":"J Infect Dis"},{"key":"2022073010085135200_ofac195-B31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12977-014-0105-9","article-title":"Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity","volume":"11","author":"Pingen","year":"2014","journal-title":"Retrovirology"},{"key":"2022073010085135200_ofac195-B32","doi-asserted-by":"crossref","first-page":"e1004722","DOI":"10.1371\/journal.ppat.1004722","article-title":"Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds","volume":"11","author":"Yang","year":"2015","journal-title":"PLoS Pathog"},{"key":"2022073010085135200_ofac195-B33","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1128\/AAC.00348-13","article-title":"Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine","volume":"57","author":"Xu","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022073010085135200_ofac195-B34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3851\/IMP2771","article-title":"Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine","volume":"19","author":"Picchio","year":"2014","journal-title":"Antivir Ther"},{"key":"2022073010085135200_ofac195-B35","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00003495-200969040-00007","article-title":"Darunavir: a review of its use in the management of HIV infection in adults","volume":"69","author":"McKeage","year":"2009","journal-title":"Drugs"},{"key":"2022073010085135200_ofac195-B36","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/infdis\/jit017","article-title":"Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe","volume":"207","author":"De Luca","year":"2013","journal-title":"J Infect Dis"},{"key":"2022073010085135200_ofac195-B37","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1086\/644505","article-title":"Transmission of drug-resistant HIV-1 is stabilizing in Europe","volume":"200","author":"Vercauteren","year":"2009","journal-title":"J Infect Dis"},{"key":"2022073010085135200_ofac195-B38","doi-asserted-by":"crossref","first-page":"10747","DOI":"10.1128\/JVI.01827-07","article-title":"Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations","volume":"82","author":"Mitsuya","year":"2008","journal-title":"J Virol"},{"key":"2022073010085135200_ofac195-B39","doi-asserted-by":"crossref","first-page":"17307","DOI":"10.1038\/s41598-019-53520-8","article-title":"Analysis of HIV-1 diversity, primary drug resistance and transmission networks in Croatia","volume":"9","author":"Oroz","year":"2019","journal-title":"Sci Rep"},{"key":"2022073010085135200_ofac195-B40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00002030-200401230-00012","article-title":"Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy","volume":"18","author":"Violin","year":"2004","journal-title":"AIDS"},{"key":"2022073010085135200_ofac195-B41","doi-asserted-by":"crossref","first-page":"e02557-19","DOI":"10.1128\/AAC.02557-19","article-title":"Antiviral activity of tenofovir alafenamide against HIV-1 with thymidine analog-associated mutations and M184V","volume":"64","author":"Margot","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2022073010085135200_ofac195-B42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/095632020701800505","article-title":"A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine","volume":"18","author":"Borroto-Esoda","year":"2007","journal-title":"Antivir Chem Chemother"},{"key":"2022073010085135200_ofac195-B43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.meegid.2018.03.002","article-title":"Phylogenetic analysis of the Belgian HIV-1 epidemic reveals that local transmission is almost exclusively driven by men having sex with men despite presence of large African migrant communities","volume":"61","author":"Verhofstede","year":"2018","journal-title":"Infect Genet Evol"},{"key":"2022073010085135200_ofac195-B44","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fmicb.2019.00613","article-title":"Earlier initiation of antiretroviral treatment coincides with an initial control of the HIV-1 sub-subtype F1 outbreak among men-having-sex-with-men in Flanders, Belgium","volume":"10","author":"Vinken","year":"2019","journal-title":"Front Microbiol"},{"key":"2022073010085135200_ofac195-B45","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1097\/QAD.0000000000000768","article-title":"A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK","volume":"29","author":"Mourad","year":"2015","journal-title":"AIDS"},{"key":"2022073010085135200_ofac195-B46","doi-asserted-by":"crossref","first-page":"32251","DOI":"10.1038\/srep32251","article-title":"A direct comparison of two densely sampled HIV epidemics: the UK and Switzerland","volume":"6","author":"Ragonnet-Cronin","year":"2016","journal-title":"Sci Rep"},{"key":"2022073010085135200_ofac195-B47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.antiviral.2014.04.001","article-title":"E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings","volume":"107","author":"Sluis-Cremer","year":"2014","journal-title":"Antiviral Res"},{"key":"2022073010085135200_ofac195-B48","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/aid.2015.0095","article-title":"Sub-epidemics explain localized high prevalence of reduced susceptibility to rilpivirine in treatment-naive HIV-1-infected patients: subtype and geographic compartmentalization of baseline resistance mutations","volume":"32","author":"Theys","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022073010085135200_ofac195-B49","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.coviro.2012.08.006","article-title":"Are subtype differences important in HIV drug resistance?","volume":"2","author":"Lessells","year":"2012","journal-title":"Curr Opin Virol"},{"key":"2022073010085135200_ofac195-B50","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.3390\/v6093535","article-title":"Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors","volume":"6","author":"Singh","year":"2014","journal-title":"Viruses"},{"key":"2022073010085135200_ofac195-B51","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1128\/AAC.00315-15","article-title":"Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor","volume":"59","author":"Xu","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022073010085135200_ofac195-B52","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/COH.0b013e328356db89","article-title":"Resistance to HIV integrase inhibitors","volume":"7","author":"Mespl\u00e8de","year":"2012","journal-title":"Curr Opin HIV AIDS"},{"key":"2022073010085135200_ofac195-B53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac195\/43370785\/ofac195.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/7\/ofac195\/45028718\/ofac195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/7\/ofac195\/45028718\/ofac195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T10:09:56Z","timestamp":1659175796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac195\/6567499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac195","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,4,12]]},"article-number":"ofac195"}}